Viemed Healthcare's Q3 revenue up 24% on Lehans acquistion

Viemed Healthcare

05/11/2025 22:37

Overview

Viemed Q3 revenue rises 24% yr/yr to $71.9 mln

Adjusted EBITDA for Q3 rises 15.5% yr/yr to $16.1 mln

Company repurchased 1.7 mln shares for $11.4 mln, enhancing shareholder value

Outlook

Viemed updates full-year revenue guidance to $271 mln-$273 mln

Company raises full-year adjusted EBITDA guidance to $60 mln-$62 mln

Result Drivers

LEHANS ACQUISITION - Strategic acquisition of Lehans Medical Equipment was immediately accretive to net income and EPS

PATIENT BASE EXPANSION - Co increased ventilator and PAP therapy patient counts significantly, contributing to revenue growth

SHARE REPURCHASE - Completion of share repurchase program enhanced EPS and demonstrated disciplined capital deployment

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Slight Miss*
$71.91 mln
$72 mln (1 Analyst)
Q3 Gross Profit
$41.35 mln
Q3 Income from Operations
$5.64 mln


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Viemed Healthcare Inc is $13.00, about 49.7% above its November 4 closing price of $6.54

The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 13 three months ago

Press Release: ID:nACS9VPDZa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)